1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Getinge AB
  6. News
  7. Summary
    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
Real-time Estimate Cboe Europe  -  08:59 2022-06-30 am EDT
234.55 SEK   -0.06%
08:01aLena Hagman, Executive Vice President Quality compliance, Regulatory & Medical Affairs, leaves Getinge
AQ
06/17PUMP / DUMP #35 : This week's gainers and losers
06/15Getinge Lowers FY22 Organic Sales Forecast Amid Lower Demand, China Lockdowns
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Getinge : to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging

04/27/2022 | 10:15am EDT
Getinge to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging

Press releases | 2022-04-27

Getinge announces today an agreement to acquire 100% of the shares in FLUOPTICS SAS, a French based leader in fluorescence imaging as an aid to surgery. The acquisition will expand Getinge's customer offering in clinical decision support by providing safe and improved operating efficiency.

FLUOPTICS, based in Grenoble, France, was founded in 2009 and has since developed NIR imaging systems, consisting of a dedicated camera and the related software, to visualize the vascularization and other tissues by the use of a fluorescent marker or by using the natural autofluorescence of the tissues. FLUOPTICS's solutions allows for visualizing physiological and biological phenomena that are invisible to the naked eye.

"With the acquisition of FLUOPTICS, we are opening a new chapter for our Surgical Workflows business by expanding into the field of advanced visualization and decision support for surgeons," says Stéphane Le Roy, President Surgical Workflows. "We will create a unique ecosystem with surgical lighting, fluorescence imaging and digital solutions for image processing and management."

The addressable global market is estimated to be more than SEK 2.5 B, recording an annual compounded average growth rate of 8 % during the forecasted period. More than 380 institutions in US, Europe and Asia are currently using the FLUOPTICS technology in their daily clinical routine with over 40,000 procedures performed. The development and the production will remain in Grenoble and will, together with Getinge's existing site in Ardon France, shape Getinge's Center of Excellence for Optics and Visualization.

"I am particularly happy to join forces with Getinge and our team is eager to leverage its impressive international network to reach all Operating Rooms in the world, "says Odile Allard, CEO of FLUOPTICS. "Together with Getinge R&D and commercial teams, we are confident that FLUOPTICS will be in the best position to accomplish our mission to establish a new standard in fluorescence imaging in the Operating Room".

Getinge will, via its subsidiary Getinge Infection Control SAS, acquire all outstanding shares in Fluoptics and will pay approximately EUR 26 M in cash on closing. Moreover, additional earn-out may be paid if agreed milestones are achieved. The acquisition will be financed through available cash. Getinge expects no material integration costs. Until closing, Fluoptics will continue to operate as a wholly independent third party.

The transaction is subject to, and conditional upon, foreign direct investment approval in France and other specific closing conditions. The transaction is expected to close before the end of the second quarter 2022.

Learn more about Fluoptics: https://fluoptics.com/en/

Media contact:

Anna Appelqvist, Vice President Corporate Communications
Phone: +46 (0)10 335 5906
E-mail: anna.appelqvist@getinge.com

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

Files

Share:

Disclaimer

Getinge AB published this content on 27 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 14:14:05 UTC.


© Publicnow 2022
All news about GETINGE AB
08:01aLena Hagman, Executive Vice President Quality compliance, Regulatory & Medical Affairs,..
AQ
06/17PUMP / DUMP #35 : This week's gainers and losers
06/15Getinge Lowers FY22 Organic Sales Forecast Amid Lower Demand, China Lockdowns
MT
06/14TRANSCRIPT : Getinge AB - Special Call
CI
06/14Getinge revises down its outlook for 2022 - long-term financial targets unchanged
AQ
06/14Getinge Revises Net Sales Guidance for the Full Year 2022
CI
04/27Getinge To Buy France's FLUOPTICS in $27.4 Million Deal
MT
04/27GETINGE : to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging
PU
04/27GETINGE AB : Ex-dividend day for final dividend
FA
04/26Resolutions at Getinge's Annual General Meeting 26 April 2022
AQ
More news
Analyst Recommendations on GETINGE AB
More recommendations
Financials
Sales 2022 29 128 M 2 852 M 2 852 M
Net income 2022 3 323 M 325 M 325 M
Net Debt 2022 2 420 M 237 M 237 M
P/E ratio 2022 19,1x
Yield 2022 1,83%
Capitalization 63 925 M 6 259 M 6 259 M
EV / Sales 2022 2,28x
EV / Sales 2023 2,05x
Nbr of Employees 10 892
Free-Float 79,8%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 234,70 SEK
Average target price 385,63 SEK
Spread / Average Target 64,3%
EPS Revisions
Managers and Directors
Mattias Sven Perjos President, Chief Executive Officer & Director
Lars Sandström Chief Financial Officer
Johan Malmquist Chairman
Anna Romberg Executive VP-Legal, Compliance & Governance
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GETINGE AB-40.60%6 259
NOVOCURE LIMITED-3.57%7 572
MASIMO CORPORATION-53.18%7 555
SHOCKWAVE MEDICAL, INC.8.99%6 957
IRAY TECHNOLOGY COMPANY LIMITED-8.15%4 941
PENUMBRA, INC.-54.67%4 908